Want to retire wealthy? I’d buy these 2 FTSE 100 dividend shares for a rising passive income

These two FTSE 100 (INDEXFTSE:UKX) stocks have the pedigree to deliver long-term dividend income growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Who doesn’t want to retire wealthy? Spending your later years free of financial worries, and making the most of all that free time, is a universal dream.

I think the best way to achieve it is to invest in a portfolio of stocks and shares, using your tax-free Stocks and Shares ISA. I’d suggest looking at these two top FTSE 100 dividend and growth stocks.

AstraZeneca

The AstraZeneca (LSE: AZN) share price has been flying lately, up 25% over the last year, and 75% over five years. This is a tribute to CEO Pascal Soriot, who has worked hard to turn the company around since joining in 2012. Investors were concerned that the pharmaceutical giant’s pipeline of new drugs was running dry, at the same time as several blockbuster treatments came off patent, allowing generic competitors to pile in to its patch.

Soriot responded by pouring money into R&D and it is starting to pay off, as the group gets regulatory approval for a number of new medicines.

AstraZeneca has raised its sales guidance twice in the last year, with full-year product sales up 12% to a hefty $23.6bn, while sales of new medicines rose 59% to $9.9bn. While the coronavirus could hit Chinese earnings, recent strong performance gives it a cushion.

Another concern is that the US Presidential election could whip up public anger over drugs pricing. However, in the longer run, our ageing society will need all the pharmaceuticals it can get, and AstraZeneca is in a good place right now. The stock currently yields just 2.8%, but that partly reflects strong recent share price growth, and you can expect dividends to rise steadily over time. AstraZeneca stock isn’t cheap, trading at 24.2 times forward earnings, but that’s because it is a quality stock.

BAE Systems

The BAE Systems (LSE: BA) share price has climbed an impressive 43% over the past 12 months, re-establishing its reputation as one of the top FTSE 100 stocks around.

Its recent full-year results also impressed, with sales up 7% to £20.1bn, and operating business cash flow up more than 30% to £1.3bn. Crucially for income investors, dividends totalled 23.2p per share for the year, up 4.5% compared to last year. This kind of growth is vital, because it means payouts are growing faster than inflation, which gives you a rising passive income from your portfolio.

One concern is its large pension deficit, but it is taking advantage of low interest rates to fund £1bn of accelerated pension deficit funding.

Despite the surge in BAE Systems stock, the shares still only trade at 13.8 times earnings, which makes now look like an attractive entry point to me. The forecast yield of 3.6% is covered twice by earnings, and as we have seen, looks set to rise much faster than inflation.

Top FTSE 100 dividend growth stocks like these two are exactly what you need to generate the rising passive income that can help you get the most out of life during your retirement.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: these FTSE 100 stocks could be among 2025’s big winners

Picking the coming year's FTSE 100 winners isn't an easy task, but we're all thinking about it at this time…

Read more »

Investing Articles

This UK dividend share is currently yielding 8.1%!

Our writer’s been looking at a FTSE 250 dividend share that -- due to its impressive 8%+ yield -- is…

Read more »

Investing Articles

If an investor put £10,000 in Aviva shares, how much income would they get?

Aviva shares have had a solid run, and the FTSE 100 insurer has paid investors bags of dividends too. How…

Read more »

Investing Articles

Here’s why I’m still holding out for a Rolls-Royce share price dip

The Rolls-Royce share price shows no sign of falling yet, but I'm still hoping it's one I can buy on…

Read more »

Investing Articles

Greggs shares became 23% cheaper this week! Is it time for me to take advantage?

On the day the baker released its latest trading update, the price of Greggs shares tanked 15.8%. But could this…

Read more »

Investing Articles

Down 33% in 2024 — can the UK’s 2 worst blue-chips smash the stock market this year?

Harvey Jones takes a look at the two worst-performing shares on the FTSE 100 over the last 12 months. Could…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Are National Grid shares all they’re cracked up to be?

Investors seem to love National Grid shares but Harvey Jones wonders if they’re making a clear-headed assessment of the risks…

Read more »

Investing For Beginners

Here’s what the crazy moves in the bond market could mean for UK shares

Jon Smith explains what rising UK Government bond yields signify for investors and talks about what could happen for UK…

Read more »